Discover the most recent news about our Company.
Triglycerides: More Than a Marker — A Driver of Cardiovascular Risk Introduction: The Residual Risk Beyond LDL Cholesterol
ASCAHIFA and Biosfer Teslab join forces to advance the diagnosis of familial hypercholesterolemia with Liposcale® On September 24, we celebrate
The Challenge of Residual Risk in Cardiovascular Health Cardiovascular diseases remain the leading cause of death worldwide.Despite preventive efforts—such as
In biomedical research, animal models represent a fundamental tool for understanding the pathophysiological mechanisms of human diseases and
Each year, cardiovascular diseases (CVD) are responsible for more than 4 million deaths in Europe, making them the leading
Each year, cardiovascular diseases (CVD) are responsible for more than 4 million deaths in Europe, making them the leading
New Findings in DLBCL Research Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma.
Obesity, a complex and multifactorial disease, currently affects more than 13% of adults worldwide, according to the latest
We Drive Our International Expansion with the Support of ACCIÓ At Biosfer Teslab, we continue to expand our international presence
Nuclear magnetic resonance (NMR) is an advanced technology that allows the analysis of various biological matrices, from blood
The XXVI Jornadas of XULA (Xarxa d’Unitats de Lípids i Arteriosclerosi) are much more than just a scientific
Metabolomics has emerged in recent years as a powerful tool for the comprehensive assessment of biochemical changes occurring
